While the accumulation of amyloid-β (Aβ) plaques and tau neurofibrillary tangles (NFTs) has long been considered central to AD pathology, increasing evidence suggests that disruption of the blood–brain barrier (BBB) may also play a pivotal role in disease progression [2, 4–6]. Here, MAPT is linked to Alzheimer disease.